Edward Jae-Hoon Kim

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Aiming Yu · 4 shared papers, 2016–2022 · strength 0.40
   • Paper A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumo… DOI 10.1007/s00280-022-04457-9↗
   • Paper Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. DOI 10.1016/j.tranon.2019.01.009↗
   • Paper Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. DOI 10.1016/j.canlet.2018.10.038↗
2. Roberto Pazo-Cid · 2 shared papers, 2020–2026 · strength 0.30
   • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
3. Mark M. Zalupski · 5 shared papers, 2013–2020 · strength 0.27
   • Paper Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemci… DOI 10.1016/j.ijrobp.2019.08.057↗
   • Paper A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. DOI 10.1007/s10637-016-0376-1↗
   • Paper Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radi… DOI 10.1016/j.ijrobp.2014.05.053↗
4. Mei‐Juan Tu · 3 shared papers, 2016–2019 · strength 0.27
   • Paper Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. DOI 10.1016/j.tranon.2019.01.009↗
   • Paper Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. DOI 10.1016/j.canlet.2018.10.038↗
   • Paper MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. DOI 10.18632/oncotarget.9999↗
5. Diane M. Simeone · 6 shared papers, 2011–2016 · strength 0.25
   • Paper A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. DOI 10.1007/s10637-016-0376-1↗
   • Paper Advances in pancreatic cancer. DOI 10.1097/mog.0b013e328349e31f↗
   • Paper The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. DOI 10.1371/journal.pone.0091983↗
6. Chang‐Il Hwang · 2 shared papers, 2017–2022 · strength 0.22
   • Paper SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. DOI 10.3389/fonc.2022.890154↗
   • Paper Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. DOI 10.1016/j.cell.2017.07.007↗
7. Luis Alfonso Rojas · 1 shared paper, 2026 · strength 0.21
   • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
8. Rocio García‐Carbonero · 1 shared paper, 2026 · strength 0.21
   • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
9. Chris Nevala-Plagemann · 1 shared paper, 2026 · strength 0.21
   • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
10. Manuel M. Hidalgo · 1 shared paper, 2026 · strength 0.21
    • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
11. Carmen Guillén‐Ponce · 1 shared paper, 2026 · strength 0.21
    • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
12. Eva Martínez de Castro · 1 shared paper, 2026 · strength 0.21
    • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
13. Teresa Mercade Macarulla · 1 shared paper, 2026 · strength 0.21
    • Paper Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomiz… DOI 10.1038/s41591-026-04705-y↗
14. Vaibhav Sahai · 3 shared papers, 2014–2020 · strength 0.20
    • Paper Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemci… DOI 10.1016/j.ijrobp.2019.08.057↗
    • Paper A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. DOI 10.1007/s10637-016-0376-1↗
    • Paper Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients wi… DOI 10.1158/1078-0432.ccr-14-1269↗
15. Thomas John Semrad · 2 shared papers, 2015–2022 · strength 0.17
    • Paper A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumo… DOI 10.1007/s00280-022-04457-9↗
    • Paper Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeuti… DOI 10.1007/s10147-014-0730-2↗
16. Dalin Zhang · 1 shared paper, 2022 · strength 0.17
    • Paper SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. DOI 10.3389/fonc.2022.890154↗
17. Yuanpei Li · 1 shared paper, 2022 · strength 0.17
    • Paper SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. DOI 10.3389/fonc.2022.890154↗
18. Cara M. Kenney · 1 shared paper, 2021 · strength 0.13
    • Paper Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic duct… DOI 10.1007/s10637-020-01044-8↗
19. Niharika B. Mettu · 1 shared paper, 2021 · strength 0.13
    • Paper Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic duct… DOI 10.1007/s10637-020-01044-8↗
20. Udo Rudloff · 1 shared paper, 2021 · strength 0.13
    • Paper Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic duct… DOI 10.1007/s10637-020-01044-8↗
21. Theodore Steven Lawrence · 2 shared papers, 2013–2020 · strength 0.13
    • Paper Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemci… DOI 10.1016/j.ijrobp.2019.08.057↗
    • Paper A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with … DOI 10.1002/cncr.28117↗
22. Justin A. Chen · 1 shared paper, 2022 · strength 0.13
    • Paper A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumo… DOI 10.1007/s00280-022-04457-9↗
23. Hari Nathan · 1 shared paper, 2020 · strength 0.10
    • Paper Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemci… DOI 10.1016/j.ijrobp.2019.08.057↗
24. Nguyen H. Tran · 1 shared paper, 2020 · strength 0.10
    • Paper Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemci… DOI 10.1016/j.ijrobp.2019.08.057↗
25. Clifford S. Cho · 1 shared paper, 2020 · strength 0.10
    • Paper Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemci… DOI 10.1016/j.ijrobp.2019.08.057↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.